Physician profile
John G Tew
NPI 1174593354
$3,273.76
in general payments reported to CMS, 2019-2025
23 companies · $552 in 2025
The $552 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $640 · 2020: $238 · 2021: $494 · 2022: $246 · 2023: $441 · 2024: $663 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,655.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $956.93 | 2019-2025 | Clareon, Rocklatan, Tryptyr |
| Ivantis, INC | $394.63 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $357.27 | 2023-2025 | Xiidra, Miebo, Vyzulta |
| Abbvie INC. | $332.77 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Novartis Pharmaceuticals Corporation | $216.86 | 2020-2023 | |
| Harrow Eye, LLC | $146.85 | 2024-2025 | Vevye, Verkazia, Flarex |
| Glaukos Corporation | $145.87 | 2019-2024 | Idose, Istent Trabecular Micro-Bypass System Model Is3 |
| Allergan, INC. | $114.73 | 2019-2022 | |
| Shire North American Group INC | $89.76 | 2019 | |
| Rxsight INC | $74.07 | 2024-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Mallinckrodt Hospital Products INC. | $59.07 | 2020-2023 | Acthar |
| Johnson & Johnson Surgical Vision, INC. | $47.59 | 2019 | |
| Thea Pharma INC. | $43.95 | 2023 | |
| Eyevance Pharmaceuticals LLC | $43.18 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $37.12 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $35.98 | 2021-2022 | |
| Horizon Therapeutics Plc | $34.49 | 2023 | Tepezza |
| Dompe US, INC. | $30.75 | 2024 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $25.35 | 2025 | Xdemvy |
| Oyster Point Pharma, INC. | $24.85 | 2022 | |
| Eyepoint US, INC. | $24.04 | 2022 | |
| Ocular Therapeutix, INC. | $21.78 | 2024 | Dextenza |
| Amgen INC. | $15.87 | 2024 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Tew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.